F Bautista1, S Gallego2, A Cañete3, J Mora4, C Diaz de Heredia2, O Cruz4, J M Fernández3, S Rives4, L Madero1, V Castel3, M E Cela5, G Ramírez6, C Sábado2, T Acha7, I Astigarraga8, A Sastre9, A Muñoz10, M Guibelalde11, L Moreno12,13. 1. CNIO-HNJ Clinical Research Unit, Servicio de Onco-Hematologia y Transplante, Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo, 65, 28009, Madrid, Spain. 2. Hospital Vall d'Hebron, Barcelona, Spain. 3. Hospital Universitario y Politécnico La Fe, Valencia, Spain. 4. Hospital Sant Joan de Déu, Barcelona, Spain. 5. Hospital Gregorio Marañón, Madrid, Spain. 6. Hospital Virgen del Rocío, Sevilla, Spain. 7. Hospital Carlos Haya, Málaga, Spain. 8. Hospital Universitario Cruces, Bilbao, Spain. 9. Hospital La Paz, Madrid, Spain. 10. Hospital Miguel Servet, Zaragoza, Spain. 11. Hospital Universitario Son Espases, Palma de Mallorca, Spain. 12. CNIO-HNJ Clinical Research Unit, Servicio de Onco-Hematologia y Transplante, Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo, 65, 28009, Madrid, Spain. lmorenom@ext.cnio.es. 13. Instituto de Investigación La Princesa, Madrid, Spain. lmorenom@ext.cnio.es.
Abstract
PURPOSE: Despite numerous advances, survival remains dismal for children and adolescents with poor prognosis cancers or those who relapse or are refractory to first line treatment. There is, therefore, a major unmet need for new drugs. Recent advances in the knowledge of molecular tumor biology open the door to more adapted therapies according to individual alterations. Promising results in the adult anticancer drug development have not yet been translated into clinical practice. We report the activity in early pediatric oncology trials in Spain. METHODS: All members of the Spanish Society of Pediatric Hematology Oncology (SEHOP) were contacted to obtain information about early trials open in each center. RESULTS: 22 phase I and II trials were open as of May 2015: 15 for solid tumors (68 %) and 7 for hematological malignancies (32 %). Fourteen (64 %) were industry sponsored. Since 2010, four centers have joined the Innovative Therapies For Children With Cancer, an international consortium whose aim is developing novel therapies for pediatric cancers. A substantial number of studies have opened in these 5 years, improving the portfolio of trials for children. Results of recently closed trials show the contribution of Spanish investigators, the introduction of molecularly targeted agents and their benefits. CONCLUSIONS: Clinical trials are the way to evaluate new drugs, avoiding the use of off-label drugs that carry significant risks. The Spanish pediatric oncology community through the SEHOP is committed to develop and participate in collaborative academic trials, to favor the advancement and optimization of existing therapies in pediatric cancer.
PURPOSE: Despite numerous advances, survival remains dismal for children and adolescents with poor prognosis cancers or those who relapse or are refractory to first line treatment. There is, therefore, a major unmet need for new drugs. Recent advances in the knowledge of molecular tumor biology open the door to more adapted therapies according to individual alterations. Promising results in the adult anticancer drug development have not yet been translated into clinical practice. We report the activity in early pediatric oncology trials in Spain. METHODS: All members of the Spanish Society of Pediatric Hematology Oncology (SEHOP) were contacted to obtain information about early trials open in each center. RESULTS: 22 phase I and II trials were open as of May 2015: 15 for solid tumors (68 %) and 7 for hematological malignancies (32 %). Fourteen (64 %) were industry sponsored. Since 2010, four centers have joined the Innovative Therapies For Children With Cancer, an international consortium whose aim is developing novel therapies for pediatric cancers. A substantial number of studies have opened in these 5 years, improving the portfolio of trials for children. Results of recently closed trials show the contribution of Spanish investigators, the introduction of molecularly targeted agents and their benefits. CONCLUSIONS: Clinical trials are the way to evaluate new drugs, avoiding the use of off-label drugs that carry significant risks. The Spanish pediatric oncology community through the SEHOP is committed to develop and participate in collaborative academic trials, to favor the advancement and optimization of existing therapies in pediatric cancer.
Entities:
Keywords:
Drug development; Early phase clinical trials; Pediatric hematology and oncology; Personalized medicine
Authors: Gilles Vassal; C Michel Zwaan; David Ashley; Marie Cecile Le Deley; Darren Hargrave; Patricia Blanc; Peter C Adamson Journal: Lancet Oncol Date: 2013-02-20 Impact factor: 41.316
Authors: Susana Rives; Jesús Estella; Pedro Gómez; Mónica López-Duarte; Purificación García de Miguel; Amparo Verdeguer; Maria José Moreno; José Luis Vivanco; José Miguel Couselo; Rafael Fernández-Delgado; Marisol Maldonado; María Tasso; Blanca López-Ibor; Francisco Lendínez; Ricardo López-Almaraz; Javier Uriz; Montserrat Melo; Ana Fernández-Teijeiro; Isidoro Rodríguez; Isabel Badell Journal: Br J Haematol Date: 2011-06-28 Impact factor: 6.998
Authors: Patrick Brown; Stephen P Hunger; Franklin O Smith; William L Carroll; Gregory H Reaman Journal: Expert Rev Hematol Date: 2009-04-01 Impact factor: 2.929
Authors: Daniel A Morgenstern; Darren Hargrave; Lynley V Marshall; Susanne A Gatz; Giuseppe Barone; Tracey Crowe; Kathy Pritchard-Jones; Stergios Zacharoulis; Donna L Lancaster; Sucheta J Vaidya; Julia C Chisholm; Andrew D J Pearson; Lucas Moreno Journal: J Pediatr Hematol Oncol Date: 2014-04 Impact factor: 1.289
Authors: Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316
Authors: Fernando Carceller; Francisco Bautista; Irene Jiménez; Raquel Hladun-Álvaro; Cécile Giraud; Luca Bergamaschi; Madhumita Dandapani; Isabelle Aerts; François Doz; Didier Frappaz; Michela Casanova; Bruce Morland; Darren R Hargrave; Gilles Vassal; Andrew D J Pearson; Birgit Geoerger; Lucas Moreno; Lynley V Marshall Journal: J Neurooncol Date: 2017-12-13 Impact factor: 4.130
Authors: F Bautista; A Cañete; G L Ramírez-Villar; J M Fernández; J L Fuster; C Diaz de Heredia; I Astigarraga; M García-Ariza; S Rives; J L Dapena; C Márquez; A Molinés; M Del M Bermúdez; S Gallego; M Del M Andrés; J Verdu-Amoros; C Hernández; M López; A Catalá; Á Lassaletta; O Cruz; M Ramírez; F Lendínez; A Carboné; J Gomez Sirvent; M Tallón; T Acha; L Moreno; A Fernández-Teijeiro Journal: Clin Transl Oncol Date: 2019-10-09 Impact factor: 3.405
Authors: Francisco Bautista; Victoria Fioravantti; Teresa de Rojas; Fernando Carceller; Luis Madero; Alvaro Lassaletta; Lucas Moreno Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452